Insulin icodec
Ultralong-acting basal insulin analogue / From Wikipedia, the free encyclopedia
Insulin icodec, sold under the brand name Awiqli, is a medication used for the treatment of diabetes to improve glycemic control.[2] It is an ultralong-acting basal insulin analogue that is developed by Novo Nordisk.[2]
Clinical data | |
---|---|
Trade names | Awiqli |
Routes of administration | Subcutaneous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C280H435N71O87S6 |
Molar mass | 6380.33 g·mol−1 |
It has a plasma half-life more than eight days[5] (compared to 25 hours of the previous longest-acting insulin analogue insulin degludec), making it a once-weekly basal insulin.[5]
Like insulin, icodec is composed of two peptide chains linked by a disulfide bridge. However, a C20 fatty diacid-containing side chain has been added for strong, reversible albumin binding; and three amino acid substitutions provide molecular stability and attenuate insulin receptor binding and clearance. Together, these modifications prolong the half-life.[6]